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Abstract.  
Background. Infection in pediatric cancer patients has become a concerning problem due to 
increasing antimicrobial resistance. The goal of this study was to determine the antimicrobial 
resistance patterns of blood isolates from pediatric oncology patients in Iran to determine if there 
was significant resistance to quinolones  
Methods. Children with cancer who were admitted with or developed fever during admission to 
Aliasghar Children’s Hospital or Mahak Hospitals July 2009 through June 2011 were eligible for 
enrollment. Two blood cultures were obtained. Antimicrobial sensitivity test was performed for 
ciprofloxacin, moxifloxacin, gatifloxacin, meropenem, cefepime, and piperacillin-tazobactam on 
isolates from children who were bacteremic.  
Results. Blood cultures were positive for 38 episodes in 169 enrolled children but 9 episodes were 
excluded as blood cultures were thought to be contaminated, yielding a bacteremia rate of 29/160 
(18%). The mean age of children and the stage of malignancy did not differ between those with and 
without bacteremia. Meropenem was the most likely antibiotic to cover isolates (97%) with 
cefepime having the lowest coverage rate (21%). Quinolone coverage ranged from 63% to 76%.  
Conclusion. Quinolones may not be suitable for use as empiric therapy in febrile pediatric oncology 
patients in Iran. 
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Introduction. Infectious diseases are common life 
threatening complications in patients with cancer, 
resulting in repeated admissions with considerable 
interruption of treatment for the underlying 
malignancy.
1
 Although the mortality rate for infectious 
diseases has been decreasing over recent decades, most 
children with febrile neutropenia are treated as 
inpatients with long durations of admission.
2
 
Recently, there are reports of successful outpatient 
management of febrile neutropenia in children with 
malignancies with oral antibiotics (typically 
quinolones).
3
 However, there is a concerning increase 
in the rate of antimicrobial resistance both in developed 
and developing countries, including quinolone 
resistance in Escherichia coli and Klebsiella 
pneumoniae. Therefore, the predicted efficacy of 
quinolones for invasive bacterial infections in children 
with malignancies can be informative as these drugs 
are used in this setting despite not yet being approved 
in children.
3
 
Aliasghar Children’s Hospital (an educational 
hospital affiliated with the Tehran University of 
Medical Sciences) and Mahak Hospital (a subspecialty 
non-profit center for children with cancer) are referral 
pediatric oncology centers in Tehran. Almost all febrile 
pediatric patients with cancer (with or without 
neutropenia) are admitted rather than treated as 
outpatients as there is no consensus on when and how 
to use risk assessments for selecting patients for 
outpatient management.
4
 
The primary objective of this study was to 
determine the in-vitro susceptibility for blood culture 
isolates in these hospitals to older and newer 
quinolones and to compare this with the susceptibilities 
to current candidates for intravenous monotherapy in 
this population. 
 
Materials and Methods. All children with any cancer 
irrespective of their stage of disease (including those 
who had finished chemotherapy or relapsed) who were 
admitted with fever or developed fever in Aliasghar 
Children’s Hospital or Mahak Hospitals from July 
2009 through June 2011 were eligible for enrollment in 
this descriptive prospective study. The same child 
could be enrolled more than once in the study. 
Informed consent was obtained from parents. 
Fever was defined as a single episode of 
temperature above 38.5 degrees C or at least two 
episodes of 38 degrees C one hour apart. For each 
febrile patient, two blood cultures were collected 
simultaneously before starting or changing the 
antibiotic therapy. Of these blood cultures, one was 
sent to the hospital laboratory and processed by the 
standard procedure and the other was sent to BACTEC 
the Pediatric Infectious Diseases Research Center 
located in Mofid Children’s Hospital and processed by 
BACTEC technology to improve the sensitivity. 
Standard methods were used for identification of 
organisms. Children who had positive blood cultures 
for common skin contaminants were considered to be 
bacteremic only if both samples were positive for the 
same microorganism. Antimicrobial sensitivity test was 
performed for ciprofloxacin, moxifloxacin, 
gatifloxacin, meropenem, cefepime, and piperacillin-
tazobactam according to Clinical and Laboratory 
Standards Institute (CLSI) methods using the standard 
disk diffusion method from MAST Co (Mast Co, 
Merseyside, UK). A questionnaire was completed for 
each patient on admission and data was analyzed by 
SPSS software version-16 using appropriate statistical 
methods. 
Data are presented as numbers and proportions. 
Continuous variables are presented as mean and 
standard deviation. 
 
Results. There were 173 febrile episodes during the 
period of study. Parental consent was not obtained for 
4 of these episodes. Blood cultures were positive for 38 
of the remaining 169 episodes but 9 episodes were 
excluded from further analysis as only a single blood 
culture was positive for a common skin contaminant, 
yielding a proven bacteremia rate of 29/160 ([18%). 
All 9 suspected contaminated blood cultures were from 
BACTEC alone. For the 29 episodes of bacteremia, 
both blood cultures were positive in 14 episodes and 
BACTEC alone in 15 episodes. Ninety-one of these 
160 cases were male (57%). The mean age of enrolled 
patients was 82 months (SD=54.4). The mean age of 
cases with bacteremia was 71.5 months (SD=55.6) and 
for those with negative blood cultures or contaminated 
blood cultures was 84.3 months (SD=57.8) (P value 
=0.27).  
Three enrolled children had two episodes of 
bacteremia during different admissions. These were not 
thought to be relapses or recurrences as two of the 
children had different organisms each time and the 
third child had the same organism but with different 
susceptibilities.  
The 160 children had 19 different types of 
malignancies (Table 1). The types of malignancies in 
enrolled patients with and without bacteremia are 
shown in Table 1 (P value=0.002). Bacteremia with 
fever was especially common with acute myeloid 
leukemia (6 of 16 episodes; 37%). There was no 
significant difference in stage of malignancy between 
those with and without bacteremia (P value=0.14). 
The organisms causing bacteremia are shown in 
Table 2 with coagulase negative staphylococci causing 
10 of the 29 cases (34%).The coverage rate was highest 
for meropenem (97%) with cefepime having the lowest  
 
Mediterr J Hematol Infect Dis 2014; 6: Open Journal System  
 
Table 1. Presence or absence of bacteremia in 160 episodes of 
fever in children with different malignancies 
Malignancy 
Group 
Total Bacteremia No bacteremia 
  
ALL 14 (17%) 69 (83%) 83 
AML 6(37%) 10(63%) 16 
Neuroblastoma 1(33%) 2(67%) 3 
Non Hodgkin’s  
lymphoma 1(50%) 1(50%) 2 
Teratoma 1(100%) 0 1 
Burkitt’s lymphoma 1(25%) 3(75%) 4 
PNET 1(25%) 3(75%) 4 
Wilm’s tumor 2(29%) 5(71%) 7 
Glioma 1(50%) 1(50) 2 
Osteosarcoma 0 1(100%) 1 
Retinoblastoma 1(13%) 7(87%) 8 
Rhabdomyosarcoma 0 12(100%) 12 
Germ cell tumor 0 3(100%) 3 
Hodgkin’s lymphoma 0 4(100%) 4 
Histiocytosis 0 1(100%) 1 
Medulloblastoma 0 5(100%) 5 
Renal cell carcinoma 0 1(100%) 1 
Ewing’s sarcoma 0 2(100%) 2 
Nasopharyngeal 
carcinoma 0 1(100%) 1 
Total 29(18%) 131(82%) 160 
AML: acute myelogenous leukemia; ALL: acute lymphoblastic 
leukemia; PNET: primitive neuroectodermal tumor. 
 
coverage rate (21%). Overall susceptibility rates for the 
three quinolones were very similar to each other, 
ranging from 63% to 76% (Table 2). 
 
Discussion. Meropenem had the highest rate of in-vitro 
coverage for organisms isolated from bacteremic 
children with malignancies in Iran. In contrast, 
cefepime susceptibility was only about 21%, a 
dramatic change from a previous study in the same 
population hospitals in which susceptibility was over 
80%.
5
 Only about 70% of the isolated organisms were 
susceptible to quinolones with the sample size being 
too small to compare ciprofloxacin to newer 
quinolones. Vital gaps in quinolone coverage included 
Staphylococcus aureus and Klebsiella species.  
In a 2003 study in adults in the United States with 
malignancies, moxifloxacin had good coverage for 
gram negative organisms except for Pseudomonas 
species for which it was inferior to ciprofloxacin and 
levofloxacin.
6
 In total, 78% of gram positive and 64% 
of gram negatives were susceptible to moxifloxacin. 
The same group published a study in 2006, showing 
that gatifloxacin offered good coverage for all but 
methicillin-resistant S. aureus, and Pseudomonas and 
Acinetobacter species.
7
 In total, 83% of gram positive 
and 64% of gram negatives were susceptible to 
gatifloxacin.
8
 
Table 2. Susceptibility rates for organisms causing bacteremia in children with malignancies (N=29)(%) 
Organism ciprofloxacin moxifloxacin gatifloxacin meropenem cefepime 
piperacillin-
tazobactam 
  
Streptococcus pneumoniae3 NA 3 (100%) 3 (100%) 3 (100%) 2 (67%) NA 
Coagulase negative 
staphylococcus10 
8 (80%) 8 (80%) 9 (90%) 10 (100%) 2 (20%) 9 (90%) 
Escherichia coli4 3 (75%) NA 3 (75%) 4 (100%) 1 (25%) 4 (100%) 
Staphylococcus.aureus3 1 (33%) 1 (33%) 1 (33%) 3 (100%) 1 (33%) 1 (33%) 
Pseudomonas aeruginosa1 1 (100%) 1 (100%) 1 (100%) 1 (100%) 0 0 
Citrobacter freundii1 1 (100%) NA 1 (100%) 1 (100%) 0 1 (100%) 
Streptococcus viridans group2 NA 2 (100%) 2 (100%) 2 (100%) 0 2 (100%) 
Enterococcus.faecalis1 0 0 0 1 (100%) 0 1 (100%) 
Enterobacter aerogenes1 1 (100%) NA 1 (100%) 1 (100%) 0 1 (100%) 
Klebsiella pneumoniae3 0 NA 1 (33%) 2 (67%) 0 1 (33%) 
Total susceptibility 15/24 (63%) 15/20 (75%) 22/29 (76%) 28/29 (97%) 6/29 (21%) 20/26 (77%) 
NA - not available as break-point not established by Clinical and Laboratory Standards Institute (CLSI) 
 
International guidelines for management of children 
with malignancies and febrile neutropenia were 
published in 2012.
9
 They describe six validated 
schemes for identifying children at low risk for serious 
infection with it not being clear which scheme 
functions best. The guidelines report that oral 
antibiotics (often quinolones) appear to be equivalent 
to intravenous antibiotics for empiric therapy in low-
risk children. In a recent meta-analysis specifically on 
the role of quinolones in children with febrile 
neutropenia, 10 studies (740 episodes of febrile 
neutropenia, all considered to be low-risk for poor 
outcomes) were included.
3
 Using varying definitions, 
treatment success was obtained in 83% of those on 
quinolone monotherapy with there being no infection-
related mortality. This success rate appeared to be 
higher than that obtained with the usual intravenous 
options. However, it is important to recognize that 
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these studies were performed in an era when quinolone 
resistance was less common than in the current study. 
In the absence of outcome data, it is difficult to predict 
what would have happened had all low risk patients in 
the current study been started on quinolones, but the 
high rate of in-vitro resistance is concerning. 
The major limitation of the current study is that only 
in-vitro data rather than clinical outcome data was 
available. Clinical and Laboratory Standards Institute 
standards do not yet exist for all antibiotics in this 
study for some of the bacteria isolated. Patients did not 
have to be neutropenic to be enrolled, and those who 
were neutropenic were not further classified as low-risk 
versus high-risk for poor outcomes. It can be difficult 
to distinguish bacteremia from contaminated blood 
cultures. Processing one blood culture by BACTEC 
technology appeared to increase both the number of 
contaminated blood cultures and the number of true 
positives.  
 
Conclusions. Although quinolones appeared to be a 
good option for children with febrile neutropenia in 
other countries, one would want to be cautious given 
the apparent high rate of resistance in Iran. Patients 
who are bacteremic with pathogens of low virulence 
such as coagulase negative staphylococci or 
enterococcus are likely to survive even if empiric 
antibiotics do not cover that organism, but the same is 
not true for E. coli or Klebsiella species, both of which 
demonstrated significant quinolone resistance is the 
current study. Given the rapid emergence of multi-
resistant gram negatives, it is imperative that rates of 
quinolone resistance be followed closely in oncology 
centers where febrile neutropenia is being managed 
with this class of drug. 
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